Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Total Current Liabilities (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Total Current Liabilities data on record, last reported at $37.8 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 47.92% year-over-year to $37.8 million; the TTM value through Sep 2025 reached $37.8 million, up 47.92%, while the annual FY2024 figure was $22.2 million, 18.46% down from the prior year.
  • Total Current Liabilities reached $37.8 million in Q3 2025 per BTAI's latest filing, up from $33.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $39.4 million in Q3 2023 and bottomed at $16.0 million in Q1 2022.
  • Average Total Current Liabilities over 4 years is $28.4 million, with a median of $27.3 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: surged 79.78% in 2023, then crashed 35.15% in 2024.
  • A 4-year view of Total Current Liabilities shows it stood at $32.9 million in 2022, then decreased by 17.12% to $27.3 million in 2023, then fell by 18.46% to $22.2 million in 2024, then skyrocketed by 70.04% to $37.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $37.8 million in Q3 2025, $33.4 million in Q2 2025, and $25.5 million in Q1 2025.